Compare ArcelorMittal SA (MT) vs Summit Therapeutics Inc (SMMT) Price & Performance

ArcelorMittal (MT) trades at $74.25, up 0.47% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings missed estimates, but revenue grew year-over-year, and the company maintains a positive outlook for H2 2026. Valuation ratios like P/S of 0.9 and P/B of 1.01 suggest reasonable pricing relative to sales and book value.

The outlook is cautiously optimistic with analyst consensus leaning Buy (50%) amid expectations of European business improvement and strategic expansions. Key risks include volatile steel demand, high capital expenditures, and macroeconomic pressures. Net cash flow remains negative, though operational cash generation is stable. Investors should weigh growth initiatives against cyclical industry headwinds.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.